India Approves First Dengue Vaccine: Here’s How QDENGA Works And Why It Could Be A Game-Changer 

New Delhi, July 22, 2026: In a major milestone for public health, India has approved its first dengue vaccine, offering new hope in the fight against one of the country’s fastest-growing mosquito-borne diseases.

The Central Drugs Standard Control Organisation (CDSCO) has granted approval to QDENGA (TAK-003), a dengue vaccine developed by Japan-based pharmaceutical company Takeda. The approval marks the first time a dengue vaccine has been officially cleared for use in India.

With India accounting for nearly one-third of the world’s reported dengue cases and infections rising sharply over the past two decades due to rapid urbanisation and climate change, health experts say the vaccine could significantly strengthen the country’s dengue prevention strategy.

What Is QDENGA?

QDENGA is designed to protect against all four dengue virus serotypes—DENV-1, DENV-2, DENV-3, and DENV-4.

One of its key advantages is that people do not need to undergo a blood test to determine whether they have previously had dengue before receiving the vaccine, unlike some earlier dengue vaccines.

The vaccine is administered as a subcutaneous injection in two doses, given three months apart.

QDENGA has already been approved in more than 40 countries, including the European Union, the United Kingdom, Brazil, Indonesia, and Argentina.

Why Is This Approval Significant for India?

Dengue has become a major public health challenge in India, particularly during and after the monsoon season. The country has witnessed an 11-fold increase in dengue cases over the past 20 years, leading to mounting pressure on hospitals and healthcare systems.

Until now, India’s dengue control efforts have largely focused on mosquito control, eliminating breeding sites, and providing supportive medical treatment. The availability of an approved vaccine adds a new preventive tool to the country’s disease-control efforts.

Key Facts About the Vaccine

Who can receive it?
The age group eligible for vaccination in India is expected to be announced separately. Internationally, the vaccine is approved for both children and adults, regardless of whether they have previously been infected with dengue.

How effective is it?
According to Phase III clinical trials involving more than 20,000 children across eight countries, QDENGA reduced the risk of hospitalisation due to dengue by up to 84% and provided 61% protection against symptomatic dengue infection.

What will it cost?
The official price in India has not yet been announced. However, Takeda has partnered with Biological E in Hyderabad to manufacture up to 50 million doses annually, a move expected to improve availability and help keep costs affordable.

Will everyone need the vaccine?
No. Health experts and the World Health Organization (WHO) emphasise that vaccination should complement—not replace—mosquito control measures, sanitation, and early diagnosis and treatment.

Will the vaccine eliminate dengue?
No. While QDENGA is expected to reduce severe disease and hospitalisations, it is not a complete solution. Dengue continues to circulate through four different virus strains, and factors such as mosquito breeding and climate change mean preventive measures will remain essential.

A Major Step Forward

Public health experts believe the approval of QDENGA could help reduce the burden of severe dengue cases and ease pressure on hospitals during peak transmission seasons.

The manufacturing partnership with Hyderabad-based Biological E is also expected to position India as an important global production hub for dengue vaccines, potentially improving access both domestically and internationally.

Health authorities are expected to issue detailed guidelines on the vaccine’s rollout, eligibility criteria, and availability in the coming weeks.